Radioresistance in prospectively Isolated Cancer Stem Cells in Esophageal Cancer Patients: RARESTEM-Organoid Study

Completed

• Conditions: 10017991; predictie respons (chemo/radiotherapie in relatie tot kankerstamcelonderzoek (CSC) op basis van tumor gerelateerde organoids; Cancerstemcell analyses in patients tumor derived organoids: assessing response of chemoradiotherapy in esophageal cancer; 10017990

• Registration Number: NL-OMON45161
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 200

Inclusion Criteria

All patients in whom a curative intended treatment/ esophageal resection can be performed.
All patient who underwent a endoscopic ultrasound (EUS) procedure for staging and had given permission for additional biopsies of the tumor and normal esophageal mucosa.
Patients should participate in the standard protocol for neo-adjuvant or definitive chemoradiotherapy

Exclusion Criteria

Patients who are medically unfit for a curative treatment
Patients who are mentally disabled or incapable to give informed consent
Patients with distant disease
Patients with other intercurrent malignancies except in- situ ca.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Question 1: Radioresistance; the effective dose 50% (ED50%) of CSCs enriched<br /><br>subpopulation will be compared with the ED50% esophageal cancer cell lines<br /><br>(control group).<br /><br>Question 2: The percentage of CSCs will be analysed for a possible correlation<br /><br>between for survival, disease-free survival and recurrences (yes vs no).</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable</p><br>